Trade Heron Therapeutics, Inc. - HRTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.52 |
| Open | 1.52 |
| 1-Year Change | -11.11% |
| Day's Range | 1.51 - 1.59 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 1.55 | 0.10 | 6.90% | 1.45 | 1.59 | 1.45 |
| Dec 19, 2024 | 1.52 | -0.05 | -3.18% | 1.57 | 1.57 | 1.46 |
| Dec 18, 2024 | 1.57 | -0.07 | -4.27% | 1.64 | 1.64 | 1.49 |
| Dec 17, 2024 | 1.63 | -0.02 | -1.21% | 1.65 | 1.67 | 1.57 |
| Dec 16, 2024 | 1.67 | 0.09 | 5.70% | 1.58 | 1.67 | 1.57 |
| Dec 13, 2024 | 1.59 | 0.02 | 1.27% | 1.57 | 1.59 | 1.51 |
| Dec 12, 2024 | 1.59 | -0.04 | -2.45% | 1.63 | 1.68 | 1.58 |
| Dec 11, 2024 | 1.68 | -0.04 | -2.33% | 1.72 | 1.73 | 1.61 |
| Dec 10, 2024 | 1.74 | 0.00 | 0.00% | 1.74 | 1.86 | 1.69 |
| Dec 9, 2024 | 1.74 | 0.16 | 10.13% | 1.58 | 1.76 | 1.53 |
| Dec 6, 2024 | 1.60 | -0.08 | -4.76% | 1.68 | 1.68 | 1.57 |
| Dec 5, 2024 | 1.69 | 0.18 | 11.92% | 1.51 | 1.78 | 1.48 |
| Dec 4, 2024 | 1.61 | -0.25 | -13.44% | 1.86 | 1.88 | 1.45 |
| Dec 3, 2024 | 1.16 | -0.05 | -4.13% | 1.21 | 1.21 | 1.11 |
| Dec 2, 2024 | 1.19 | 0.00 | 0.00% | 1.19 | 1.22 | 1.18 |
| Nov 29, 2024 | 1.17 | 0.01 | 0.86% | 1.16 | 1.19 | 1.15 |
| Nov 27, 2024 | 1.13 | 0.07 | 6.60% | 1.06 | 1.16 | 1.06 |
| Nov 26, 2024 | 1.07 | -0.06 | -5.31% | 1.13 | 1.13 | 1.05 |
| Nov 25, 2024 | 1.12 | 0.05 | 4.67% | 1.07 | 1.14 | 1.06 |
| Nov 22, 2024 | 1.05 | 0.00 | 0.00% | 1.05 | 1.07 | 1.04 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Heron Therapeutics, Inc. Company profile
About Heron Therapeutics Inc
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Heron Therapeutics Inc revenues decreased 3% to $86.3M. Net loss decreased 3% to $220.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects "Research and development - Balancing va decrease of 39% to $66.4M (expense), Stock-based Compensation in SGA decrease of 24% to $11.8M (expense).
Equity composition
Common Stock $.01 Par, 02/10, 50M auth., 40,143,227 issd. Insiders own 6.70%. IPO: 8/87, 2M shares @ $7.00 by Allen & Co. 2/92, private placement of 1,150,000 units (1 Share + 1 Warrant). 5/01, Name changed from Advanced Polymer Systems, Inc. FY'01 fncls. are restated. 05/07, 1-for-4 reverse stock split. 01/14, 1-for-20 Reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
4242 Campus Point Court, Suite 200
SAN DIEGO
CALIFORNIA 92121
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com